Canary Speech Raises $13 Million for Vocal Biomarker Technology

Canary Speech, known for their AI-powered vocal biomarker technology for healthcare, has successfully raised $13 million in Series A funding. This round was led by Cortes Capital, LLC, with significant contributions from Sorenson Communications, LLC., SMK (Japan), and Hackensack Meridian Health.

Canary Speech has a robust portfolio of nine issued patents that protect its unique vocal biomarker applications in healthcare. The company plans to use the new funds to expand its team and support its rapid growth, driven by both technological advancements and increased demand from the healthcare sector.

"There are technologies that truly disrupt the way healthcare is administered, and Canary is committed to pioneering vocal biomarkers and ambient listening for the betterment of healthcare”

- Henry O’Connell, co-founder and CEO of Canary Speech.

“We couldn't be more excited to support Canary Speech's mission to drive change in the healthcare industry with their scalable technology and best-in-class team”

- Ryan Tidwell, Chief Investment Officer at Cortes Capital.